[HTML][HTML] The changing therapeutic landscape of metastatic renal cancer
JC Angulo, O Shapiro - Cancers, 2019 - mdpi.com
The practising clinician treating a patient with metastatic clear cell renal cell carcinoma
(CCRCC) faces a difficult task of choosing the most appropriate therapeutic regimen in a …
(CCRCC) faces a difficult task of choosing the most appropriate therapeutic regimen in a …
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
A Ingels, R Campi, U Capitanio, D Amparore… - Nature Reviews …, 2022 - nature.com
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the …
Background The role of upfront cytoreductive nephrectomy (CN) for metastatic renal cell
carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective To …
carcinoma (mRCC) in the era of immune checkpoint inhibitors is unclear. Objective To …
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients …
Abstract Objectives European Urology Association guidelines suggest the use of integrated
prognostic systems to assess oncologic outcomes after surgery in patients with localized …
prognostic systems to assess oncologic outcomes after surgery in patients with localized …
Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. results from a …
M Marchioni, M Kriegmair, M Heck, T Amiel… - European urology …, 2021 - Elsevier
Background Selection of patients for upfront cytoreductive nephrectomy (CN) in metastatic
renal cell carcinoma (mRCC) has to be improved. Objective To evaluate a new scoring …
renal cell carcinoma (mRCC) has to be improved. Objective To evaluate a new scoring …
Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma
Background Cytoreductive nephrectomy (CN) plays an important role in the treatment of a
subgroup of metastatic renal cell carcinoma (mRCC) patients. Objective We aimed to …
subgroup of metastatic renal cell carcinoma (mRCC) patients. Objective We aimed to …
[HTML][HTML] Treatment strategies for clear cell renal cell carcinoma: Past, present and future
J Yang, K Wang, Z Yang - Frontiers in Oncology, 2023 - frontiersin.org
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney
cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and …
cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and …
Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study
G Procopio, G Apollonio, F Cognetti, R Miceli… - European Urology …, 2019 - Elsevier
Background In selected metastatic renal cell carcinoma (mRCC) patients, radical
metastasectomy followed by observation is a potential strategy. It is still to be defined …
metastasectomy followed by observation is a potential strategy. It is still to be defined …
[HTML][HTML] Synchronous versus metachronous metastatic disease: impact of time to metastasis on patient outcome—results from the International Metastatic Renal Cell …
Background Patients with metastatic renal cell carcinoma (mRCC) may present with primary
metastases (synchronous disease) or develop metastases during follow-up (metachronous …
metastases (synchronous disease) or develop metastases during follow-up (metachronous …
Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines
The role of cytoreductive nephrectomy (CN) patients with metastatic renal cell carcinoma
(mRCC) is unclear. To define the proportion of symptomatic mRCC, to investigate the impact …
(mRCC) is unclear. To define the proportion of symptomatic mRCC, to investigate the impact …